Market Closed -
Swiss Exchange
09:01:30 26/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
89.5
CHF
|
-0.56%
|
|
+4.64%
|
+5.46%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,14,715
|
2,15,682
|
1,96,476
|
1,94,400
|
2,07,226
|
1,99,642
|
-
|
-
|
Enterprise Value (EV)
1 |
2,30,615
|
2,40,182
|
2,04,667
|
2,03,434
|
2,19,237
|
2,12,291
|
2,10,827
|
2,05,468
|
P/E ratio
|
30.4
x
|
26.7
x
|
8.2
x
|
28.3
x
|
14.1
x
|
19.4
x
|
16.7
x
|
15.1
x
|
Yield
|
3.19%
|
3.56%
|
3.83%
|
3.87%
|
3.79%
|
3.69%
|
3.82%
|
4.02%
|
Capitalization / Revenue
|
4.53
x
|
4.43
x
|
3.81
x
|
3.85
x
|
4.56
x
|
4.09
x
|
3.94
x
|
3.91
x
|
EV / Revenue
|
4.86
x
|
4.94
x
|
3.96
x
|
4.02
x
|
4.82
x
|
4.35
x
|
4.17
x
|
4.02
x
|
EV / EBITDA
|
14.6
x
|
14.3
x
|
11.2
x
|
10.9
x
|
12.2
x
|
11
x
|
10.3
x
|
9.83
x
|
EV / FCF
|
17.9
x
|
20.5
x
|
15.4
x
|
17
x
|
16.6
x
|
15.2
x
|
13.7
x
|
12.6
x
|
FCF Yield
|
5.58%
|
4.87%
|
6.49%
|
5.87%
|
6.01%
|
6.6%
|
7.33%
|
7.93%
|
Price to Book
|
3.87
x
|
3.78
x
|
2.9
x
|
3.23
x
|
4.42
x
|
4.46
x
|
4.42
x
|
4.15
x
|
Nbr of stocks (in thousands)
|
22,64,608
|
22,74,506
|
22,37,092
|
21,50,980
|
20,55,460
|
20,40,406
|
-
|
-
|
Reference price
2 |
94.81
|
94.83
|
87.83
|
90.38
|
100.8
|
97.84
|
97.84
|
97.84
|
Announcement Date
|
29/01/20
|
26/01/21
|
02/02/22
|
01/02/23
|
31/01/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
47,445
|
48,659
|
51,626
|
50,545
|
45,440
|
48,785
|
50,616
|
51,104
|
EBITDA
1 |
15,809
|
16,845
|
18,246
|
18,613
|
17,937
|
19,290
|
20,468
|
20,898
|
EBIT
1 |
14,112
|
15,416
|
16,588
|
16,665
|
16,372
|
18,126
|
19,240
|
19,542
|
Operating Margin
|
29.74%
|
31.68%
|
32.13%
|
32.97%
|
36.03%
|
37.15%
|
38.01%
|
38.24%
|
Earnings before Tax (EBT)
1 |
8,940
|
9,878
|
26,137
|
8,371
|
9,123
|
12,843
|
14,491
|
15,043
|
Net income
1 |
7,147
|
8,072
|
24,021
|
6,955
|
14,854
|
10,372
|
11,895
|
12,811
|
Net margin
|
15.06%
|
16.59%
|
46.53%
|
13.76%
|
32.69%
|
21.26%
|
23.5%
|
25.07%
|
EPS
2 |
3.120
|
3.550
|
10.71
|
3.190
|
7.150
|
5.056
|
5.867
|
6.472
|
Free Cash Flow
1 |
12,875
|
11,691
|
13,282
|
11,945
|
13,179
|
14,004
|
15,444
|
16,290
|
FCF margin
|
27.14%
|
24.03%
|
25.73%
|
23.63%
|
29%
|
28.71%
|
30.51%
|
31.88%
|
FCF Conversion (EBITDA)
|
81.44%
|
69.4%
|
72.79%
|
64.18%
|
73.47%
|
72.59%
|
75.45%
|
77.95%
|
FCF Conversion (Net income)
|
180.15%
|
144.83%
|
55.29%
|
171.75%
|
88.72%
|
135.01%
|
129.83%
|
127.16%
|
Dividend per Share
2 |
3.025
|
3.375
|
3.360
|
3.500
|
3.823
|
3.608
|
3.740
|
3.934
|
Announcement Date
|
29/01/20
|
26/01/21
|
02/02/22
|
01/02/23
|
31/01/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
13,229
|
12,531
|
12,781
|
12,543
|
12,690
|
12,953
|
13,622
|
11,782
|
11,423
|
11,829
|
12,253
|
12,477
|
12,766
|
11,905
|
12,155
|
EBITDA
|
4,274
|
4,407
|
4,989
|
4,783
|
4,473
|
-
|
4,668
|
-
|
4,224
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
3,819
|
4,083
|
4,270
|
4,282
|
4,030
|
4,413
|
4,668
|
4,405
|
3,821
|
4,537
|
4,588
|
4,697
|
4,542
|
4,790
|
4,895
|
Operating Margin
|
28.87%
|
32.58%
|
33.41%
|
34.14%
|
31.76%
|
34.07%
|
34.27%
|
37.39%
|
33.45%
|
38.35%
|
37.45%
|
37.64%
|
35.58%
|
40.24%
|
40.27%
|
Earnings before Tax (EBT)
1 |
16,951
|
2,669
|
2,042
|
1,919
|
1,741
|
2,740
|
2,769
|
1,552
|
2,377
|
3,129
|
3,856
|
3,880
|
3,665
|
-
|
-
|
Net income
1 |
16,308
|
2,222
|
1,695
|
1,575
|
1,466
|
2,293
|
2,316
|
1,513
|
8,480
|
2,688
|
2,777
|
2,814
|
2,515
|
-
|
-
|
Net margin
|
123.27%
|
17.73%
|
13.26%
|
12.56%
|
11.55%
|
17.7%
|
17%
|
12.84%
|
74.24%
|
22.72%
|
22.66%
|
22.55%
|
19.7%
|
-
|
-
|
EPS
2 |
7.290
|
1.000
|
0.7700
|
0.7300
|
0.6900
|
1.090
|
1.110
|
0.7300
|
4.140
|
1.310
|
1.358
|
1.386
|
1.252
|
-
|
-
|
Dividend per Share
2 |
3.360
|
-
|
-
|
-
|
3.500
|
-
|
-
|
-
|
3.823
|
-
|
0.9494
|
0.9494
|
0.9494
|
1.014
|
1.014
|
Announcement Date
|
02/02/22
|
26/04/22
|
19/07/22
|
25/10/22
|
01/02/23
|
25/04/23
|
18/07/23
|
24/10/23
|
31/01/24
|
23/04/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
15,900
|
24,500
|
8,191
|
9,034
|
12,011
|
12,649
|
11,185
|
5,827
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.006
x
|
1.454
x
|
0.4489
x
|
0.4854
x
|
0.6696
x
|
0.6557
x
|
0.5464
x
|
0.2788
x
|
Free Cash Flow
1 |
12,875
|
11,691
|
13,282
|
11,945
|
13,179
|
14,004
|
15,444
|
16,290
|
ROE (net income / shareholders' equity)
|
17.5%
|
23.5%
|
22.7%
|
21%
|
25.4%
|
32.2%
|
38%
|
37.5%
|
ROA (Net income/ Total Assets)
|
8.89%
|
6.45%
|
10.9%
|
10.7%
|
12.4%
|
10.7%
|
12.8%
|
14.2%
|
Assets
1 |
80,393
|
1,25,215
|
2,21,201
|
64,915
|
1,20,082
|
96,509
|
92,941
|
90,135
|
Book Value Per Share
2 |
24.50
|
25.10
|
30.30
|
28.00
|
22.80
|
21.90
|
22.10
|
23.60
|
Cash Flow per Share
2 |
5.880
|
5.950
|
6.670
|
6.480
|
6.910
|
7.710
|
8.280
|
8.540
|
Capex
1 |
2,257
|
1,275
|
1,378
|
1,198
|
1,060
|
1,251
|
1,251
|
1,289
|
Capex / Sales
|
4.76%
|
2.62%
|
2.67%
|
2.37%
|
2.33%
|
2.56%
|
2.47%
|
2.52%
|
Announcement Date
|
29/01/20
|
26/01/21
|
02/02/22
|
01/02/23
|
31/01/24
|
-
|
-
|
-
|
Last Close Price
97.84
USD Average target price
108.5
USD Spread / Average Target +10.88% Consensus |
1st Jan change
|
Capi.
|
---|
| +5.46% | 200B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | -9.61% | 195B | | -6.26% | 145B | | -11.77% | 144B |
Other Pharmaceuticals
|